Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

Схожие документы

• Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
  по: El Guerrab, Abderrahim, et al.
  Опубликовано: (2020)
• Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
  по: Abderrahim El Guerrab, et al.
  Опубликовано: (2011-01-01)
• Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
  по: El Guerrab, Abderrahim, et al.
  Опубликовано: (2011)
• BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
  по: Dufour, Robin, et al.
  Опубликовано: (2015)
• The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
  по: Clémence Dubois, et al.
  Опубликовано: (2019-03-01)